- Home
- PLRX vs CDXC Comparison
PLRX vs CDXC Comparison
Compare PLRX & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- CDXC
- Stock Information
- Founded
- PLRX 2015
- CDXC 1999
- Country
- PLRX United States
- CDXC United States
- Employees
- PLRX N/A
- CDXC N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- PLRX Health Care
- CDXC Health Care
- Exchange
- PLRX Nasdaq
- CDXC Nasdaq
- Market Cap
- PLRX 641.5M
- CDXC 572.6M
- IPO Year
- PLRX 2020
- CDXC N/A
- Fundamental
- Price
- PLRX $14.72
- CDXC $5.99
- Analyst Decision
- PLRX Strong Buy
- CDXC Strong Buy
- Analyst Count
- PLRX 7
- CDXC 2
- Target Price
- PLRX $40.50
- CDXC $8.00
- AVG Volume (30 Days)
- PLRX 459.1K
- CDXC 732.2K
- Earning Date
- PLRX 11-07-2024
- CDXC 10-31-2024
- Dividend Yield
- PLRX N/A
- CDXC N/A
- EPS Growth
- PLRX N/A
- CDXC N/A
- EPS
- PLRX N/A
- CDXC 0.02
- Revenue
- PLRX N/A
- CDXC $91,668,000.00
- Revenue This Year
- PLRX N/A
- CDXC $18.64
- Revenue Next Year
- PLRX N/A
- CDXC $20.72
- P/E Ratio
- PLRX N/A
- CDXC $301.89
- Revenue Growth
- PLRX N/A
- CDXC 9.95
- 52 Week Low
- PLRX $10.22
- CDXC $1.36
- 52 Week High
- PLRX $19.62
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- PLRX 56.15
- CDXC 40.09
- Support Level
- PLRX $13.14
- CDXC $5.87
- Resistance Level
- PLRX $15.27
- CDXC $7.79
- Average True Range (ATR)
- PLRX 0.75
- CDXC 0.34
- MACD
- PLRX 0.00
- CDXC -0.24
- Stochastic Oscillator
- PLRX 58.27
- CDXC 6.67
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.